Enovix (NASDAQ:ENVX - Get Free Report) updated its first quarter 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of -0.210--0.150 for the period, compared to the consensus earnings per share estimate of -0.170. The company issued revenue guidance of $3.5 million-$5.5 million, compared to the consensus revenue estimate of $6.2 million.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on ENVX. Janney Montgomery Scott downgraded shares of Enovix from a "buy" rating to a "neutral" rating and set a $10.00 target price on the stock. in a report on Thursday, October 31st. Cantor Fitzgerald restated an "overweight" rating and issued a $30.00 price target on shares of Enovix in a research report on Thursday. Craig Hallum decreased their target price on shares of Enovix from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Benchmark reissued a "buy" rating and set a $25.00 price target on shares of Enovix in a report on Wednesday, October 30th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Enovix currently has an average rating of "Moderate Buy" and a consensus target price of $20.30.
Check Out Our Latest Stock Report on ENVX
Enovix Price Performance
Shares of NASDAQ ENVX traded down $0.76 during trading on Friday, reaching $10.72. The company had a trading volume of 10,754,726 shares, compared to its average volume of 5,803,739. Enovix has a 52 week low of $5.70 and a 52 week high of $18.68. The stock has a market cap of $1.91 billion, a PE ratio of -7.39 and a beta of 1.87. The company has a debt-to-equity ratio of 0.99, a quick ratio of 3.61 and a current ratio of 3.77. The business's 50 day moving average price is $11.15 and its 200-day moving average price is $10.29.
Enovix (NASDAQ:ENVX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. The business had revenue of $9.72 million during the quarter, compared to the consensus estimate of $8.77 million. Enovix had a negative net margin of 963.17% and a negative return on equity of 96.99%. Analysts expect that Enovix will post -1.01 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Betsy S. Atkins sold 75,000 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $9.73, for a total transaction of $729,750.00. Following the completion of the sale, the director now directly owns 99,497 shares of the company's stock, valued at $968,105.81. The trade was a 42.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 15.70% of the stock is currently owned by insiders.
Enovix Company Profile
(
Get Free Report)
Enovix Corporation designs, develops, and manufactures lithium-ion batteries. It serves wearables and IoT, smartphone, laptops and tablets, industrial and medical, and electric vehicles industries. The company was founded in 2007 and is headquartered in Fremont, California.
See Also

Before you consider Enovix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovix wasn't on the list.
While Enovix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.